±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 684  |  »Ø¸´: 1

²ÊºçÌǵÄÃØÃÜ

гæ (СÓÐÃûÆø)

[½»Á÷] Ôõô·­Òë°¡ÇóÖú£¬JBT-101ÊÇʲôÇó¸æÖª

abstract
Ajulemic acid, a side-chain analog of D8
-THC-11-oic acid, was designed as a potent therapeutic agent free
of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid
have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these
discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than
previously reported in the literature and compared its cannabinoid receptor binding constants with those
obtained using several other preparations from different sources. Whereas CB2 binding did not vary
greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified
product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239)
showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that
for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using
JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus,
earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light
of the data now obtained using JBT-101.

·¢×ÔСľ³æAndroid¿Í»§¶Ë
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

²ÊºçÌǵÄÃØÃÜ

гæ (СÓÐÃûÆø)

abstract
Ajulemic acid, a side-chain analog of D8
-THC-11-oic acid, was designed as a potent therapeutic agent free
of the psychotropic adverse effects typical of most cannabinoids. Subsequent studies of ajulemic acid
have yielded widely divergent findings on the occurrence of these adverse effects. To help resolve these
discrepancies, we have prepared highly purified ajulemic acid using a different synthetic method than
previously reported in the literature and compared its cannabinoid receptor binding constants with those
obtained using several other preparations from different sources. Whereas CB2 binding did not vary
greatly among all of the samples, the CB1 binding showed a wide range of affinities. The highly purified
product (JBT-101) reported here had the weakest affinity for CB1 while the original preparation (HU-239)
showed the strongest affinity for CB1. The CB1/CB2 ratio of affinities was 12.3 for JBT-101 whereas that
for HU-239 was 0.19, a 65-fold difference. Functional responses such as catalepsy and hypothermia using
JBT-101 versus HU-239 displayed reduced CB1 activity in keeping with the receptor binding data. Thus,
earlier conclusions on the limited therapeutic index for ajulemic acid need to be reconsidered in the light
of the data now obtained using JBT-101.

·¢×ÔСľ³æAndroid¿Í»§¶Ë
2Â¥2017-02-07 10:27:37
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ²ÊºçÌǵÄÃØÃÜ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 366Çóµ÷¼ÁÒ»Ö¾Ô¸¶«±±´óѧ +7 ÔËÆøÀ´µÃÈôÓÐËÆÎ 2026-04-02 7/350 2026-04-02 14:47 by °¶ÉϵÄÒ»ÌõÓã
[¿¼ÑÐ] 266Çóµ÷¼Á +4 ѧԱ97LZgn 2026-04-02 4/200 2026-04-02 13:03 by yulian1987
[¿¼ÑÐ] ²ÄÁÏרҵÇóµ÷¼Á +10 ÔÂÔÂÄñľ 2026-04-01 10/500 2026-04-02 12:57 by wxiongid
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©Àí¹¤´óѧ±¾¿Æ211²ÄÁϹ¤³Ì294Çóµ÷¼Á +8 mikasaµÄΧ½í 2026-03-28 9/450 2026-04-02 12:09 by ms629
[¿¼ÑÐ] 348Çóµ÷¼Á +6 СÀÁ³æ²»ÀÁÁË 2026-03-27 7/350 2026-04-02 11:18 by sanrepian
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +5 ÏàÐűػá¹ââÍòÕ 2026-03-31 6/300 2026-04-02 10:16 by guoweigw
[¿¼ÑÐ] 0817»¯¹¤Ñ§Ë¶µ÷¼Á +11 ŬÁ¦Éϰ¶ÖУ¡ 2026-03-31 11/550 2026-04-01 20:30 by Àµ´ºÑÞ
[¿¼ÑÐ] µ÷¼Á +3 ºÃºÃ¶ÁÊé¡£ 2026-04-01 5/250 2026-04-01 15:39 by ºÃºÃ¶ÁÊé¡£
[¿¼ÑÐ] ²ÄÁÏר˶306Ó¢Ò»Êý¶þ +7 z1z2z3879 2026-03-31 7/350 2026-04-01 14:50 by ZXlzxl0425
[¿¼ÑÐ] 291Çóµ÷¼Á +3 ÃÔÃÉľľ 2026-04-01 4/200 2026-04-01 11:07 by ÄæË®³Ë·ç
[¿¼ÑÐ] 326Çóµ÷¼Á +4 áÌáÌ×Ð 2026-03-31 4/200 2026-04-01 09:58 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] ÍÁľ304Çóµ÷¼Á +5 ¶¥¼¶²Á²Á 2026-03-31 5/250 2026-04-01 08:15 by fdcxdystjk£¤
[¿¼ÑÐ] 335Çóµ÷¼Á +3 321* 2026-03-31 4/200 2026-04-01 00:00 by 321*
[¿¼ÑÐ] Çóµ÷¼Á ÉúÎïѧ 377·Ö +6 zzll03 2026-03-31 6/300 2026-03-31 17:33 by ÌÆãå¶ù
[¿¼ÑÐ] 329Çóµ÷¼Á£¬Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ£¬²ÄÁϹ¤³Ì£¨085601£© +6 СС»úÁ鳿 2026-03-29 12/600 2026-03-31 16:58 by ¼Çʱ¾2026
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +4 ´Þwj 2026-03-31 4/200 2026-03-31 11:56 by jp9609
[¿¼ÑÐ] 293·ÖÇóµ÷¼Á£¬ÍâÓïΪ¶íÓï +5 ¼ÓÒ»Ò»¾Å 2026-03-31 5/250 2026-03-31 09:39 by zhshch
[¿¼ÑÐ] 304²ÄÁÏÇóµ÷¼Á +5 ÖÓllll 2026-03-26 5/250 2026-03-30 19:37 by Ô´_2020
[¿¼ÑÐ] Çóµ÷¼Á +7 ÕùÈ¡¾Åµã˯ 2026-03-28 8/400 2026-03-28 21:07 by ÕùÈ¡¾Åµã˯
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤£¨0856£©304ÇóBÇøµ÷¼Á +8 Çñgl 2026-03-27 8/400 2026-03-28 12:42 by ÌÆãå¶ù
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û